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Abstract
Background: The immunoglobulin A isotypes of  anti-cyclic citrullinated peptide antibodies (ACPA) and rheumatoid factor 
(RF) are associated with disease severity and progression in Caucasian rheumatoid arthritis (RA) patients, as well as with genetic 
predisposition and tobacco use. 
Objectives: To compare levels of  ACPA-IgA and RF-IgA with those of  ACPA-IgG and cRF in a cohort of  black South Afri-
can RA patients and healthy controls.To investigate the relationship between IGA autoantibodies and disease severity, genetic 
predisposition and tobacco use
Methods: RF-IgA and ACPA-IgA were determined in a cohort of  predominantly black South African RA patients (n=75) in 
relation to serodiagnostic and prognostic potential, as well as tobacco use and genetic predisposition. Healthy control subjects 
were included to determine sensitivity, specificity and predictive values.
ACPA-IgG/IgA and RF-IgA were determined by enzyme immunoassay and hs-CRP and cRF by nephelometry. Cotinine levels 
were  determined by ELISA.
Results: The frequencies of  ACPA-IgA and RF-IgA were 31% and 88% respectively compared to 88% for both types of  tradi-
tional autoantibody procedures. ACPA-IgA was significantly higher (p=0.007) in patients with short disease duration, while lin-
ear regression analysis revealed a positive relationship with baseline disease activity scores. Levels of  ACPA-IgG and ACPA–IgA 
were significantly higher in tobacco users who carried the HLA shared epitope. 
Conclusion: Although lacking in serodiagnostic superiority over cRF and ACPA-IgG, inclusion of  RF-IgA and ACPA-IgA in 
autoantibody panels may provide insights into disease pathogenesis, interactions between tobacco usage and HLA genotype in 
the production of  potentially disease-triggering ACPA-IgA antibodies.
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Introduction
Rheumatoid arthritis (RA) is a crippling disease charac-
terized by chronic inflammation of  the articular joints 
of  patients leading to cartilage destruction and disease 
progression. The incidence is around 1-3% of  the gen-
eral population with a significantly higher prevalence in 
females. The inclusion of  measurement of  rheumatoid 
factor (RF) and anti-citrullinated peptide (ACPA) anti-
bodies, generally composite RF (cRF) and ACPA-IgG, 
in the 2010 ACR/EULAR RA classification criteria is an 
indication of  the sero-diagnostic utility of  measurement 
of  these auto-antibodies in RA1 and is well established 
worldwide2-5.
The profile and complex interplay of  various RA-associ-
ated auto-antibodies and their different isotypes is influ-
enced by the ethnic, genetic and environmental factors, 
with RF isotypes having been shown to be associated 
with a poor prognosis in Chinese and Indian, but not in 
Malay RF patients6, while in Caucasians, ACPA-IgA have 
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been shown to be associated with severe disease and ra-
diographic progression11,12. However, less is known about 
the diagnostic and prognostic potential of  measurement 
of  ACPA and RF auto-antibodies of  the IgA isotype in 
other ethnicities with RA, as well as their associations 
with prominent disease risk factors, specifically tobacco 
use (i.e. cigarettes and snuff) and positivity for the human 
leucocyte antigen - shared epitope (HLA-SE).
These issues have been addressed in the current study 
in which the levels and prevalence ACPA-IgA and RF-
IgA auto-antibodies have been compared with those of  
ACPA-IgG and cRF in a cohort of  disease-modifying an-
ti-rheumatic drug (DMARD)-naïve, black, predominantly 
female, South African patients with RA, and a control 
group of  healthy individuals, the findings of  which may 
be broadly applicable to other populations.Additional 
aims included investigation of  the relationships of  these 
IgA auto-antibodies with: i) disease severity as measured 
by the simplified disease activity score (SDAI); and ii) 
genetic predisposition and tobacco use. As mentioned 
above these potentially important issues have not been 
investigated previously in our geographic region.
 
Patients & methods
The study was approved by the Research Ethics Commit-
tees of  the Faculties of  Health Sciences of  the Univer-
sities of  the Witwatersrand and Pretoria and conformed 
to good clinical and laboratory practice and the Helsin-
ki declaration. Patients were recruited from the Chris 
Hani Baragwanath Academic hospital (CHBAH, Soweto, 
South Africa) and Steve Biko Academic Hospital (SBAH, 
Pretoria, South Africa) Rheumatology Out-patient clin-
ics.  Ethics certificate reference numbers: 09/2017 (UP) 
and M150513 (WITS).
Informed consent, signed by each patient, was explained 
and monitored by the attending physician. Although the 
informed consent document was available only in En-
glish, a translator was present at both the CHBAH and 
SBAH Rheumatology clinics to ensure that patients fully 
understood the nature of  their participation in the study. 
No financial compensation was offered, and it was ex-
plained to the participants that the results of  this study 
may lead to better understanding of  their disease. Healthy 
controls where anonymously sourced from the South Af-
rican Blood Transfusion Service.
This study was a retrospective, cross-sectional study the 
primary objective of  which was to determine the utility 
of  measurement of  immunoglobin A (IgA) rheumatoid 
factor (RF) and anti-cyclic citrullinated peptide antibodies 
(ACPA) in sero-diagnosis and prognosis of  rheumatoid 
arthritis (RA), as well as their relationships with known 
risk factors and roles as predictive biomarkers of  disease 
severity in black South African patients with RA. To our 
knowledge, the study is the first of  its type undertaken 
in sub-Saharan Africa. The study cohort consisted of  a 
sub-group (n=75) of  black African patients that formed 
part of  a previously described cohort7, all diagnosed with 
RA according to the 1987 ACR RA criteria, all of  whom 
were DMARD-naïve at baseline. Methods for serological 
measurement cRF and ACPA-IgG have been described 
previously for this cohort of  RA patients7-9.
Twenty healthy individuals were used as controls, matched 
in so far as possible for age, ethnicity and gender to de-
termine if  commercial stated cut-off  values for RF and 
ACPA IgA are valid, to assist in calculating specificity, 
sensitivity and positive/ negative predictors and cotinine 
levels to determine tobacco use cut-offs.
Venous blood was collected in 2x5ml test tubes, 1 with 
added clotting factor and 1 containing the anti-coagulant, 
EDTA. The serum tubes were left to clot and centrifuged 
thereafter for 10 minutes at 2000 x g. The serum was re-
moved, aliquoted and stored at -20°C until analyzed. The 
EDTA anti-coagulated blood was used the extract whole 
genomic DNA using the Maxwell Promega automated 
DNA extraction instrument and Promega Maxwell® 16 
Tissue DNA purification kits (Promega Corporation, 
Madison, USA).
Clinical disease activity was recorded using the standard 
classification for SDAI; remission = ≤ 3, low disease ac-
tivity (LDA) = >3 - ≤11, mild disease activity (MDA) = 
>11 - ≤26 and high disease activity (HDA) >2612.
EliA ACPA-IgA and RF-IgA were measured using fluo-
rescence enzyme immunoassay (FEIA) on the automat-
ed Phadia 250 platform (Phadia AB, Uppsala, Sweden). 
Cut-off  values to determine positivity for the individual 
auto-antibodies were as follows:  >10 units/millilitre (U/
ml) serum for EliA ACPA-IgG and ACPA-IgA, >20 IU/
ml for EliA RF IgA, >15 U/ml for cRF. High-sensitivi-
ty serum C-reactive protein (CRP) concentrations were 
measured by latex-enhanced laser nephelometry (Siemens 
South Africa, Midrand, South Africa) and the results ex-
pressed as micrograms (µg)/ml.
Cotinine was determined using an ELISA kit (Calbiotech 
Inc., Spring Valley, CA, USA). The results are expressed 
as nanograms (ng/ml). A cut-off  above 10 ng/ml was 
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taken as indicative of  active tobacco use as recommended 
by the product insert.
The molecular procedures used for HLA-DRB1 typing 
and HLA-SE categorization have been described previ-
ously8. Briefly, purity and concentrations of  the extracted 
DNA were determined, and molecular analysis carried 
out using a high-resolution rSSO typing technique util-
ising Luminex® bead technology for HLA-DRB1 alleles 
(LABType HD Class II DRB1 Typing Test, One-Lamb-
da, Thermo Fisher Scientific, USA) and alleles assigned 
using One Lambda Fusion software. The HLA-SE has 
been classified and validated according to the RAA amino 
acid sequence at positions 72-74 of  the third hypervari-
able region of  the HLA-DRB1 gene and assigned SS if  
both HLA-DRB1 alleles express the RAA motif, or SX 
if  only one HLA-DRB1 allele expresses the RAA mo-
tif. Further classification of  the SE-sequence beyond the 
RAA amino acid sequences at positions 72 to 74 have a 
modulatory effect (positions 70 and 71). Glutamine (Q) 
or arginine (R) at position 70 of  the 3rd hypervariable re-
gion of  the HLA-DRB1 gene conferred a high risk of  
severe disease, while aspartic acid (D) is associated with 
low risk. Lysine (K) at position 71 was indicative of  the 
highest risk, while arginine (R) alanine (A) or glutamic 
acid (E) were classified as low risk10.
Expression of  results and statistical analysis
Results are expressed as the median values with inter-
quartile ranges. Descriptive and inferential statistics tech-
niques were used in the analyses. Tests for association 
of  contingency tables were performed using two-tailed 
Chi2 tests. One-way ANOVA was performed using the 
Dunn and Kruskal-Wallis tests for non-parametric data 
for more than 2 groups, or the Mann-Whitney test when 
2 groups were compared with Bonferroni correction 
where applicable. Correlation coefficients were derived 
from non-parametric Spearman’s rank correlation test 
and correlation matrices using the Sidak’s method p value 
correction for multiple testing. Statistical significance was 
determined by p-value <0.05 and confidence intervals of  
95%. The analyses were done using STATA13.
The raw data is stored electronically for 15 years as per 





The demographics of  the group of  RA patients, as well 
as seropositivity rates for the biomarkers and SE-related 
data are summarized in Table 1.
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Table 1. Patient demographics, disease indices, tobacco use, HLA-SE categories  
and autoantibody positivity rates in the group of RA patients 
  
n=75 N (%) Median iqr  (min-max) 
        
Age(years) 
 
47.8 19 (18 - 75) 
Females 61 (81)     
Males 14 (19)     
  
Disease Duration (months) 
 
8.5 11.9 (2 - 25) 
<6 months 24 (32)     
6 to 12 months 27 (36)     
>12 months 24 (32)     
        
SDAI 
 
40 25 (5 - 76) 
LDA, n(%) 2 (3)     
MDA, n(%) 17 (23)     
HDA, n(%) 56 (75)     
  




Erosions, n(%) 31 (47)     
 
Tobacco use 28 (37)     
HLA-SE 71 (95)     
Homozygous 41 (55)     
Heterozygous 30 (40)     
  
    
hs-CRP(mg/dl) 
 
13 22 (1 - 113) 
        
RF(UI/ml) 
 
161 403 (4 - 1720) 




RF positivity 66 (88)     
ACPA(U/ml)   494839 (2 - 1621) 








The sensitivities, specificities, positive predictive values 
(PPVs), negative predictive values (NPVs), prevalence 
rates and Likelihood Ratios for cRF, ACPA-IgG, RF-IgA 
and ACPA-IgA in the group of  RA patients are shown in 
Table 2. These demonstrate that cRF and ACPA are the 
best overall predictors of  disease. ACPA-IgA antibodies, 
on the other hand, have the best specificity and PPV of  
the group of  biomarkers, but show lesser sensitivity and 
NPV in comparison with cRF and ACPA. Likelihood ra-
tios for cRF and ACPA rank the highest with cRF at 9.32. 
Importantly, RF-IgA and ACPA-IgA were inferior to the 
traditional cRF and ACPA-IgG sero-diagnostic biomark-
ers recommended by the ACR 2010.
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Table 2. Sensitivities, Specificities, PPVs, NPVs and Likelihood Ratios for the various auto antibodies. 
  










cRF 86.7 (76.8 - 93.4) 90.7 (82.5– 95.9) 89.0 (79.5– 95.2) 88.6 (80.1– 94.4) 9.32 
ACPA 86.7 (76.8 - 93.4) 86.0(77.3– 92.3) 83.3 (73.2 – 90.8) 88.9 (80.5– 94.5) 6.19 
RF-IgA 50.0 (33.8- 66.2) 58.2(32.9– 81.6) 74.1 (53.7– 88.9) 33.3 (17.2 – 52.8) 1.20 
ACPA-IgA 30.7 (20.5 – 42.4) 95.0 (75.1 – 99.9) 95.8 (78.9 – 99.9) 26.8 (16.9 – 38.6) 1.76 
Highest results achieved are in BOLD 
 
The overall combination of  reactivities and cross-reac-
tivities of  all the auto-antibodies are demonstrated in a 
Venn diagram as Figure 1.
The healthy control subjects had median values (iqr) 
of  16 (53) IU/ml and 2 (3) IU/ml for RF-IgA and AC-
PA-IgA, respectively.  RF-IgA seropositivity amongst the 
healthy control subjects was 41% (95% CI: 19% - 67%), 
while ACPA-IgA demonstrated a positivity rate of  18% 
(95% CI: 5%- 46%).
 
 
Figure 1. Venn diagram of positive reactivity patterns of ACPA-IgG, cRF, ACPA-IgA RF-IgA individually as well 
as cross-reactivity patterns between these biomarkers. 
The Venn diagram indicates that 31% (n=23) of RA patients had cRF and ACPA autoantibodies of both 
serotypes (IgG and IgA), while 48% (n=36) were positive for ACPA-IgG, cRF and RF-IgA, but not for ACPA-
IgA.    
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Disease severity (SDAI scores & disease duration at 
baseline)
Duration since onset of  symptoms in months, SDAI 
scores and the presence of  erosions at presentation were 
used as markers of  disease severity. At baseline, 25% 
(n=19) of  patients were scored as MDA and 75% (n=56) 
as HDA,  while no patients were in remission or LDA. 
Linear regression analysis revealed a statistically signifi-
 
 
Figure 2. Median values of ACPA, and ACPA-IgA in patients categorised according to HLA-SE homozygosity 
(SS) and heterozygosity (SX). 
Values were standardised (z-scores) to display on common y-axis (standardisation: x* = (x-m)/SD 
Where m is the mean of x, and SD is the standard deviation of x). 
  
cant positive relationship between ACPA-IgA and SDAI 





 Tobacco users (serum cotinine >10ng/ml) presented with 
a higher SDAI score at baseline than non-users (p=0.036) 
using the Mann-Whitney U-test. ACPA -IgA levels were 
higher in tobacco users than non-users (p=0.007) in the 
group of  patients with disease duration of  <12 months, 
but not in those with disease duration >12 months.
 
HLA-SE
Table 1 indicates that 71 (95%) patients had an HLA-
SE allele, of  which 30 (40%) were heterozygous (SX) i.e. 
had 1 of  the SE-associated alleles and 55% where homo-
zygous (SS) for HLA-SE. Only 4 (5%) of  the patients 
expressed no HLA-SE phenotype (XX) in keeping with 
previously described findings in this cohort of  patients8. 
This showed that the 71 patients with HLA-SE alleles 
could be categorized as High Risk (HR) and Low Risk 
(LR), according to the amino acids at position 70 and 71. 
The HR and LR groups consisted of  48 (68%) and 23 
(31%) patients respectively. A further subdivision con-
sisting of  homozygous, heterozygous, LR and HR HLA-
SE allele permutations revealed the following groupings: 
i) 23 (31%) patients had both the LR and HR HLA-SE 
alleles (DUAL), ii) 10 (13%) were homozygous for the 
HR alleles (HoHR), iii) 17 (23%) were heterozygous for 
the HR alleles (HeHR), iii) 8 (11%) were homozygous for 
the LR alleles (HoLR), iv) 13 (17%) were heterozygous 
for the LR alleles (HeLR), and v) 4(5%) had no HLA-SE 
alleles.
As shown in Figure 2, statistically significant differences 
in serum levels of  ACPA-IgG (p = 0.009) and ACPA-IgA 
(p=0.032) were noted when comparing the SS vs. SX 
HLA-SE allele expression groups, with the homozygous 
(SS) patients having consistently higher median autoan-
tibody titres than their heterozygous (SX) counterparts. 
This was not apparent in the cases of  both cRF and RF-
IgA.
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As shown in Figure 3A, the median titers of  ACPA-IgA 
auto-antibodies in tobacco users show a trend, albeit in-
significant (p=0.078), towards higher values, while the 
data shown in Figure 3B indicate an association between 
HLA-SE homo- and heterozygosity, tobacco use and AC-
PA-IgA, which reaches statistical significance only in the 
heterozygous group ( p=0.028). This may be explained by 
the presence of  the HR modulatory gene present in 57% 
(n=17) present in the SX group, whereas in the SS group 
only 24% (n=10) of  patients have the HR associated ami-
no acid sequence. The majority 56% (n=23) of  the SS 
patients express the LR modulatory gene in combination 
with the HR gene, with a further 20% (n=8) homozygous 
for LR.  These findings are in agreement with the involve-
ment of  the HR HLA-SE genes in the immunopathogen-
esis of  RA, potentiated by tobacco use.
 
 
Figure 3A. Median ACPA-IgA values in RA tobacco users and non-users showing a trend towards higher 
ACPA-IgA titres in users of tobacco. 
Figure 3B. Median ACPA-IgA values in tobacco users and non-users categorised according to Shared Epitope 
homozygosity (SS) and heterozygosity (SX). 
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Discussion
The current study demonstrates a lack of  diagnostic or 
predictive value of  measurement of  RF-IgA relative to 
that of  cRF in this study group of  DMARD-naïve, Af-
rican RA patients. Measurement of  ACPA-IgA, on the 
other hand, demonstrated an extremely high specificity 
and positive predictive value, as well as a positive asso-
ciation with disease activity, but was notably lacking in 
both sensitivity and negative predictive value in compar-
ison with both ACPA-IgG and cRF. Assuming that these 
observations can be extrapolated to other population 
groups, they appear to argue against the clinical utility of  
measurement of  either RF-IgA or ACPA-IgA as diagnos-
tic adjuncts to cRF and ACPA11,12.
Interestingly, however, tobacco usage, which was associ-
ated with higher disease activity on presentation, was also 
associated with higher levels of  ACPA-IgA, specifically 
in those RA patients categorized as having disease dura-
tion of  <12 months. Higher levels of  ACPA-IgA prior 
to disease onset may be a reflection of  epitope spread-
ing and isotype expansion, a phenomenon well described 
in RA13 In addition, when comparing RA tobacco users 
with RA non-tobacco users, a statistically significant, pos-
itive association between smoking, SE genotype and se-
rum concentrations of  ACPA-IgA was also evident14-16. 
These observations are of  possible significance in rela-
tion to the role of  smoking and HLA genotype in the 
immunopathogenesis of  RA, seemingly strengthening 
the link with smoking-related protein citrullination in the 
airway mucosa17-19, and possibly the gastrointestinal mu-
cosa20,21, resulting in interactions of  citrullinated proteins 
with SE-expressing T lymphocytes, leading to the pro-
duction of  potentially pathogenic ACPA-IgA auto-anti-
bodies13. In this context, it is, however, noteworthy, that 
tobacco usage in the current cohort of  RA patients is 
predominantly inhalation of  powdered tobacco (snuff), 
as opposed to active smoking, with both types of  tobacco 
usage resulting in equivalent circulating concentrations of  
cotinine22, suggesting, that like active smoking, usage of  
smokeless tobacco products, particularly those that are 
inhaled, may also predispose to development of  RA.
 
Notwithstanding the relatively small number of  patients, 
which is a limitation of  this study, it is, however, note-
worthy that similar sized or smaller cohort studies have 
been published in a number of  peer-reviewed journals as 
illustrated in the systematic review article by Peter Tay-
lor et al.22 The findings of  our study do, however, appear 
to indicate the lack of  superiority of  RF-IgA and AC-
PA-IgA over cRF and ACPA-IgG in the sero-diagnosis 
of  RA. On the other hand, the finding of  associations of  
ACPA-IgA with tobacco usage and HLA genotype indi-
cates that this augmentative combination of   risk factors 
for development and severity of  RA in Black South Afri-
cans is similar to that described for their counterparts of  
Caucasian origin. Clearly, usage of  any type of  tobacco 
product is to be discouraged in those identified as being 
at high risk for development of  RA, or who are in the 
early stages of  the disease.
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